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Summary
Background: Medetomidine suppresses cardiovascular function and reduces gastrointestinal motility in horses mainly through peripheral a2-
adrenoceptors. Vatinoxan, a peripheral a2-antagonist, has been shown experimentally to alleviate the adverse effects of some a2-agonists in horses.
However, vatinoxan has not been investigated during constant-rate infusion (CRI) of medetomidine in standing horses.
Objectives: To evaluate effects of vatinoxan on cardiovascular function, gastrointestinal motility and on sedation level during CRI of medetomidine.
Study design: Experimental, randomised, blinded, cross-over study.
Methods: Six healthy horses were given medetomidine hydrochloride, 7 lg/kg i.v., without (MED) and with (MED+V) vatinoxan hydrochloride, 140 lg/
kg i.v., followed by CRI of medetomidine at 3.5 lg/kg/h for 60 min. Cardiorespiratory variables were recorded and borborygmi and sedation levels were
scored for 120 min. Plasma drug concentrations were measured. The data were analysed using repeated measures ANCOVA and paired t-tests as
appropriate.
Results: Initially heart rate (HR) was significantly lower and mean arterial blood pressure (MAP) significantly higher with MED compared with MED+V.
For example at 10 min HR (mean  s.d.) was 26  2 and 31  5 beats/minute (P = 0.04) and MAP 129  15 and 103  13 mmHg (P<0.001)
respectively. At 10 min, cardiac index was lower (P = 0.02) and systemic vascular resistance higher (P = 0.001) with MED than with MED+V.
Borborygmi were reduced after MED; this effect was attenuated by vatinoxan (P<0.001). All horses were sedated with medetomidine, but the mean
sedation scores were reduced with MED+V until 20 min (6.8  0.8 and 4.5  1.5 with MED and MED+V, respectively, at 10 min, P = 0.001). Plasma
concentration of dexmedetomidine was significantly lower in the presence of vatinoxan (P = 0.01).
Main limitations: Experimental study with healthy, unstimulated animals.
Conclusions: Vatinoxan administered i.v. with a loading dose of medetomidine improved cardiovascular function and gastrointestinal motility during
medetomidine CRI in healthy horses. Sedation was slightly yet significantly reduced during the first 20 min..
The Summary is available in Portuguese – see Supporting Information
Keywords: horse; sedation; medetomidine; vatinoxan; MK-467; a2-antagonist
Introduction
The a2-adrenoceptor agonists (a2-agonists) administered by constant-rate
infusions (CRI) are commonly used to provide sedation for standing surgical
and diagnostic procedures. Medetomidine, with its pharmacologically
active enantiomer dexmedetomidine, is the most selective a2-agonist in
clinical use and provides sedation and analgesia through centrally mediated
effects [1]. In horses, its pharmacokinetic profile, with a short half-life,
makes it attractive for use in CRI [2,3], although it is registered for use only
in small animals. Infusion rates for stable sedation with medetomidine and
dexmedetomidine in horses have been described [2–4]. However,
medetomidine shares the various adverse peripheral effects of all a2-
agonists. Most notably, medetomidine causes vasoconstriction, leading
initially to hypertension and baroreceptor-mediated reflex bradycardia [5],
later followed by a centrally mediated hypotension [4]. At equipotent doses,
medetomidine-induced bradycardia is shorter in duration than that induced
by detomidine [6]. Additionally, medetomidine decreases mixed venous
oxygen tension [4]. Dexmedetomidine also decreases borborygmi and
increases blood glucose concentrations in horses [7].
Vatinoxan (previously MK-467 or L-659,066) is a peripherally acting a2-
adrenoceptor antagonist. In rats and marmosets, vatinoxan crosses the
blood–brain barrier minimally such that its concentration in the brain
remains far below that present in blood [8]. Thus, vatinoxan may reduce
the peripheral adverse effects of a2-agonists without interfering with
their centrally mediated sedative or analgesic effects. In previous equine
studies, vatinoxan prevented the adverse cardiovascular effects of
simultaneously administered single doses of the a2-agonists medetomidine
[9], detomidine [10] and romifidine [11]. Although vatinoxan increased the
volume of distribution and clearance of detomidine [10] and romifidine [11]
in horses, it did not have clinically relevant effects on the degree of
sedation. Furthermore, vatinoxan improved gastrointestinal motility in
horses when administered with single doses of detomidine [10,12] and
romifidine [11].
The objective of this study was to evaluate the impact of vatinoxan on
cardiorespiratory and gastrointestinal parameters during a CRI of
medetomidine in standing, healthy horses. In addition, the effects of
vatinoxan on sedation and plasma concentrations of the enantiomers of
medetomidine (dexmedetomidine and levomedetomidine) were investi-
gated. We hypothesised that vatinoxan would alleviate the cardiovascular
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and gastrointestinal depression caused by medetomidine but would not
lead to clinically relevant loss of sedation.
Materials and methods
Horses
Six horses (4 Standardbreds and 2 Warmbloods; 3 mares and 3 geldings)
with a median age of 10 years (range, 5–19 years) and median body
weight of 513 kg (range, 460–557 kg) were used in the study. The horses
were considered healthy on the basis of clinical examination and results of
complete blood count and serum biochemistry. Horses were fed hay and
had free access to water, except during the experiment. Feed, but not
water, was withheld for 2 h before and after the experiment.
Instrumentation
Instrumentation was performed with horses unmedicated and restrained in
stocks. First, vascular catheters were aseptically placed with 2 mL of 2%
mepivacaine (Scandicain)a injected subcutaneously for local anaesthesia. A
central venous catheter (Cavafix Certo)b was placed into the cranial vena
cava via the distal part of the left jugular vein. The correct location of the
central venous catheter was verified by characteristic pressure wave forms
on the monitor screen (S/5 compact Critical Care Monitor)c. The proximal
part of the same left jugular vein was then used for a standard intravenous
catheter (Intraflon)d. An arterial catheter (BD Arterial cannula)e was placed
into the previously subcutaneously relocated [13] right common carotid
artery. Finally, a lithium sensor (LiDCO Plus)f was connected to the arterial
catheter for cardiac output (Qt) determination by the lithium dilution
method (LiDCO Plus)f [14]. Lithium was prepared as previously described
by adding 1.875 mL of 8 mol/L lithium chloride to 100 mL of saline (0.9%)
solution to obtain a concentration of 150 mmol/L [12]. Standard values of
6.2 mmol/L (10 g/dL) (haemoglobin) and 140 mmol/L (sodium) were
entered. The calculation of Qt was later performed with the true values of
haemoglobin and sodium at each time point as measured from the arterial
blood samples.
Treatments and data collection
Prior to drug administration, baseline values for all measurements were
determined. Heart rate and respiratory rate were obtained by auscultation,
and Qt, systolic (SAP), mean (MAP) and diastolic (DAP) arterial blood pressure
and central venous pressure (CVP) were recorded. Arterial and venous blood
was anaerobically collected into heparinised syringes (Pico50)g and stored
on ice. Blood gas analysis (ABL800 Flex)g was performed within 10 min of
sample collection. Values were temperature-corrected on the basis of
concurrently recorded rectal temperature. An investigator (M.R.R., R.C.B.)
blinded to the treatment assignment assessed sedation according to a
predefined sedation scoring system [15] (Supplementary Item 1). The same
investigator then auscultated gastrointestinal borborygmi and scored it
following a previously described scale [16] (Supplementary Item 2).
Each horse received two treatments in a randomised cross-over design,
separated by at least 7 days. Horses were administered medetomidine
hydrochlorideh (Dorbene) (7 lg/kg, i.v.) over 15 s through the jugular
catheter at time 0 without (MED) or with (MED+V) vatinoxan hydrochloridei
(140 lg/kg i.v.). The drugs were diluted in saline to achieve a total injection
volume of 10 mL. Five min following the bolus, a CRI of medetomidine was
initiated at a rate of 3.5 lg/kg/h and continued for 60 min with an infusion
pump (Perfusor)b.
Heart rate, respiratory rate, SAP, DAP, MAP and CVP were recorded at
5, 10, 20, 30, 45, 60, 90 and 120 min. From 10 min onwards, at the same
time points, the Qt and blood gas values from arterial and venous blood
samples were measured and sedation and gastrointestinal borborygmi
were scored by the same blinded investigator.
In addition, arterial blood samples (10 mL) were collected into EDTA-
containing tubes at 10, 30, 60, 90 and 120 min and stored at room
temperature (20°C). Plasma was separated by centrifugation at 400 g for
10 min ≤6 h after sample collection and stored at 20°C until analysed for
drug concentrations.
The following calculations were performed retrospectively: cardiac index
(CI), stroke volume index (SVI), systemic vascular resistance index (SVRI),
arterial oxygen content (CaO2), venous oxygen content (CvO2), left ventricular
workload (LVW), oxygen delivery index (DO2I), oxygen consumption index
(VO2I) and oxygen extraction (O2ER) [17–19] (Supplementary Item 3).
Pharmacokinetic parameters were calculated using commercially available
software (Phoenix WinNonlin)j using non-compartmental analysis with the
following settings: linear trapezoidal linear/log interpolation and uniform
weighting for all analysed drugs, time range slope and dose type i.v. infusion
for dex- and levomedetomidine, and best fit slope and dose type i.v. bolus
for vatinoxan.
Analysis of plasma drug concentrations
The concentrations of drugs in plasma were determined with high-
performance liquid chromatography-tandem mass spectrometry in
separate aliquots that were processed under specific conditions for the
two drugs. The concentrations were determined after solid-phase
extraction with well extraction plates (Sep-Pak tC18)k with racemic
d3-medetomidine (Toronto Research Chemicals)
l and RS-79948 (Tocris
Biosciences)m as the respective internal standards. For dexmedetomidine
and levomedetomidine analysis, chiral separation with an a1-acid
glycoprotein (AGP) column (Chiralpak)n was performed and 10 mmol/L
ammonium acetate (pH 4.5) and acetonitrile containing 0.1% formic acid
were used as solvents. For vatinoxan, reversed-phase separation with a
2.1 9 150 mm, 3.5 lm C18 column (SunFire)
k and a gradient solvent
system (0.1% formic acid in water and acetonitrile) was used. Quantitative
detection was performed in multi-reaction monitoring mode with a triple
quadrupole mass spectrometer (4000 QTrap)o. For dexmedetomidine and
levomedetomidine and for d3-medetomidine, the respective precursor ions
(m/z) were 201.2 and 204.2. The fragment ions (m/z) monitored and used
for quantitation were 95.1 for dexmedetomidine and levomedetomidine
and 98.05 for d3-medetomidine. For vatinoxan and RS-79948, the
respective precursor ions (m/z) scanned were 419.3 and 365.3. The
fragment ions monitored and used for quantitation were 200.1 for
vatinoxan and 190.2 for RS-79948. The chromatograms were then
processed using MDS Sciexo software. The linear concentration range for
the assay of dexmedetomidine and levomedetomidine was from 0.100 to
10.0 ng/mL. The inter-assay accuracy of the quality control samples (at
three different concentration levels, 0.225, 1.0 and 8.0 ng/mL) ranged from
101.2 to 108.5% for dexmedetomidine and from 99.4 to 108.4% for
levomedetomidine. The linear concentration range of the assay of
vatinoxan was from 25 to 460 ng/mL. The accuracy of the quality control
samples (at three different concentration levels, 70, 250 and 380 ng/mL)
ranged from 102.5 to 113.6%.
Data analysis
All statistical analyses were performed using commercially available
software (SASp and SPSSq). The sample size was chosen based on practical
considerations and previous evidence from comparable studies [10,12]
indicating that to detect clinically relevant differences in the investigated
parameters a sample size of six horses would be sufficient.
Change from baseline was used as the response with all variables,
excluding plasma drug concentration data. The differences between
treatments in change from baseline values were assessed with repeated
measures analysis of covariance models. The model consisted of a
baseline covariate, the main effects of treatment, period, sequence and
time point of measurement and two-way interactions of period*time
point, sequence*time point and treatment*time point as fixed effects,
and main effect of horse and two-way interaction terms of period*horse
and time point*horse as random effects. No carry-over effect was
expected to arise in the study and was therefore not tested. The
normality assumptions were checked for all responses with Kolmogorov–
Smirnov tests. For SVI, DO2I and VO2I, logarithmic transformation was
computed to normalise the distributions. For SAP, a square
transformation and for CI an inverse transformation was used. With all
transformed change variables, the model was fitted for changes in the
transformed response. From the fitted models, estimates of treatment
effect were calculated over time and by time point using model
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contrasts. In addition, estimates for the within treatment changes were
computed similarly from the same model.
For plasma concentration values and areas under the time-plasma
concentration curves, normality was investigated with the Shapiro–Wilk
test. The data were normally distributed and paired t-tests were
applied.
P≤0.05 were considered statistically significant.
Results
Cardiovascular effects
Heart rate was overall significantly lower with MED than with MED+V; the
lowest HR was 24  3 beats/minute and 30  3 beats/minute with MED
and MED+V, respectively (Fig 1). With MED+V, MAP immediately
decreased and was significantly lower than with MED until 60 min, with a
nadir of 100  19 mmHg at 30 min (Fig 2). MAP remained unchanged
from baseline with MED until 45 min, after which MAP significantly
decreased, with a nadir of 97  10 mmHg at 120 min (Fig 2). Similar
changes were observed in SAP and DAP (Table 1). A significant increase in
CVP was observed with MED until 20 min, after which CVP remained at
baseline levels, whereas a significant decrease in CVP was observed with
MED+V at 30 min, lasting until 90 min.
With MED, the CI decreased and SVRI increased immediately and were
significantly different from MED+V at 10 min (Table 1 and Fig 3). After
cessation of the CRI, there was a significant decrease in SVRI and increase in
SVI with MED (Table 1 and Fig 3). In comparison, no significant changes in
CI, SVRI and SVI were detected with MED+V. Left ventricular workload
significantly decreased after medetomidine administration, without
significant differences between the treatments (Table 1).
Respiratory rate and arterial and venous blood gas
analysis
Respiratory rate, PaO2, PvO2 and DO2I significantly decreased, and O2ER
and CO2 tensions in arterial and venous blood significantly increased over
time with both treatments (data for 5 and 45 min and for CO2 tension are
not shown) (Table 2). However, significant differences were detected only
in PvO2 and in O2ER, in which the changes from baseline were significantly
greater with MED than with MED+V. No consistent changes in VO2I were
detected (Table 2). Arterial glucose concentrations did not change from
baseline with MED+V whereas they increased significantly with MED, with
the highest mean value of 9.6  2.4 mmol/L (Table 2).
Borborygmi and sedation scores
While medetomidine significantly decreased the borborygmi score, the
decrease was overall significantly smaller and briefer with MED+V than
with MED (Table 1). The sedation score increased significantly from
baseline in all horses within 10 min after administration of medetomidine;
scores were increased from 0.7  0.5 to 6.8  0.8 and from 0.5  0.6 to
4.5  1.5 with MED and MED+V respectively. Sedation scores returned to
60
MED
MED+V
*a
b
b b b b
b
b
b
*a
*a
*a
a a
a
a55
50
45
40
35
H
ea
rt
 r
at
e 
(b
ea
ts
/m
in
)
30
25
20
15
10
0 5 10 20 30 45
Time (min)
60 90 120
Fig 1: Mean (s.d.) heart rate of 6 horses after administration of medetomidine
hydrochloride 7 lg/kg i.v. alone (MED) or with vatinoxan hydrochloride 140 lg/kg
i.v. (MED+V) at 0 min and constant-rate infusion of medetomidine 3.5 lg/kg/h
administered from 5 to 65 min. Significant differences (P≤0.05) are labelled as
within (a) MED and (b) MED+V with respect to baseline and as (*) between the
treatments at given time points.
160
* *
*
*
*a *a *a
a
b
b
b
b
b b b b
MED
MED+V
150
140
130
M
ea
n 
ar
te
ri
al
 b
lo
od
 p
re
ss
ur
e 
(m
m
H
g)
120
110
100
90
80
70
0 10 20 30 40 50 60
Time (min)
70 80 90 100 110 120
Fig 2: Mean (s.d.) arterial blood pressure of 6 horses after administration of
medetomidine hydrochloride 7 lg/kg i.v. alone (MED) or with vatinoxan
hydrochloride 140 lg/kg i.v. (MED+V) at 0 min and constant-rate infusion of
medetomidine 3.5 lg/kg/h administered from 5 to 65 min. Significant differences
(P≤0.05) are labelled as within (a) MED and (b) MED+V with respect to baseline
and as (*) between the treatments at given time points.
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Fig 3: Mean (s.d.) systemic vascular resistance index of 6 horses after
administration of medetomidine hydrochloride 7 lg/kg i.v. alone (MED) or with
vatinoxan hydrochloride 140 lg/kg i.v. (MED+V) at 0 min and constant-rate
infusion of medetomidine 3.5 lg/kg/h administered from 5 to 65 min. Significant
differences (P≤0.05) are labelled as within (a) MED with respect to baseline and
as (*) between the treatments at given time points.
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pre-treatment levels by 120 min after drug administration (Table 1). The
increase in sedation score was significantly larger with MED than with
MED+V at 10 and 20 min.
Pharmacokinetic results
The areas under the time-plasma concentration curves of
dexmedetomidine and levomedetomidine were significantly smaller in the
presence of vatinoxan, thus indicating lower plasma exposure to
dexmedetomidine (Table 3, Fig 4). Indeed, the concentrations of
dexmedetomidine in plasma during the CRI of medetomidine were also
significantly lower with MED+V than with MED (Fig 4).
Discussion
The results of this study support the hypothesis that a single i.v. bolus of
vatinoxan prevents the cardiovascular and gastrointestinal effects induced
by a loading dose and CRI of medetomidine without major effects on
TABLE 1: Cardiovascular measurements, borborygmi and sedation scores (mean  s.d.) of 6 horses after administration of medetomidine
hydrochloride 7 lg/kg i.v. alone (MED) or with vatinoxan hydrochloride 140 lg/kg i.v. (MED+V) at 0 min and constant-rate infusion of
medetomidine 3.5 lg/kg/h administered from 5 to 65 min
Variable Treatment Baseline 5 min 10 min 20 min 30 min 45 min 60 min 90 min 120 min
SAP (mmHg) MED 161  23.3 159  16.5 159  24.6 154  17.7 146  17.2† 141  15.4† 134  14.4† 123  10.2† 123  8.6†
MED+V 166  15.3 130  20†* 127  14.5†* 130  18.3†* 125  22.3†* 128  17.1†* 124  16.6† 128  16.5† 148  13.8†
DAP (mmHg) MED 104  12.7 116  14.8† 114  13.5 106  12.3 102  11 100  9.4 99  17.6 84  8.3† 81  8.0†
MED+V 97  15.2 93  17.6* 89  10* 89  15.1* 85  15.5†* 82  15.6†* 86  11.8 89  11.5 93  12.8
Mean CVP
(mmHg)
MED 11.0  3.9 15.0  3† 13.7  3† 12.3  2.4 11.5  3.5 11.0  2.4 9.7  1.6 9.5  4 8.2  4.2†
MED+V 11.5  3.3 9.2  2.4* 9.7  2.7* 9.3  3.5* 7.2  3.7†* 8.2  2.6†* 8.0  4.2† 8.8  2.8† 11.0  3.7
Cardiac index
(mL/min/kg)
MED 80.8  22.1 – 52.8  6.9† – 61.4  3.9 – 72.4  14.6 86.1  26.3 120  45.4†
MED+V 77.0  14.6 – 70.2  12.6* – 69.3  9.9 – 67.7  8.1 73.1  18.1 92.9  25.3
Stroke volume
index (mL/kg)
MED 2.0  0.5 – 2.1  0.4 – 2.2  0.2 – 2.6  0.5† 2.6  0.8† 3.7  1.4†
MED+V 2.2  0.5 – 2.4  0.5 – 2.3  0.4 – 2.3  0.3 2.3  0.4 2.4  0.4*
Left ventricular
workload (kg m)
MED 72.2  25.7 – 47.5  7.0† – 52.3  10.9 – 57.1  10 58.2  14.1 79.8  27.6
MED+V 64.9  14.7 – 47.3  7.3† – 48.6  14.3† – 47.4  7.4† 54.4  20.1† 74.6  26.1
Borborygmi score MED 4.9  1.5 – 1.0  0.8† 0.3  0.3† 0.3  0.4† 0.6  0.5† 0.3  0.4† 0.6  0.6† 1.4  0.7†
MED+V 5.1  2.0 – 4.3  2.5* 3.4  1.6†* 2.3  1.2†* 2.6  1.2†* 2.3  0.9†* 5.3  1.6* 4.5  2.0*
Sedation score MED 0.7  0.5 – 6.8  0.8† 6.8  0.4† 6.5  0.6† 6.3  0.8† 5.2  1.7† 2.8  2.3† 1.5  1.1
MED+V 0.5  0.6 – 4.5  1.5†* 5.2  1.3†* 5.5  1.1† 5.3  1.2† 4.7  0.8† 2.0  1.1† 1.2  0.4
SAP, systolic arterial blood pressure; DAP, diastolic arterial blood pressure; CVP, central venous pressure. Significant differences (P≤0.05) are labelled as
(†) within treatment with respect to baseline at given time point and (*) between the treatments in change from baseline at given time point.
TABLE 2: Respiratory rate, arterial and venous blood gas data and calculated variables derived from it, and plasma glucose concentrations
(mean  s.d.) of the same 6 horses as in Table 1
Variable Treatment Baseline 10 min 20 min 30 min 60 min 90 min 120 min
Respiratory rate (breaths/min) MED 20  9 12  5† 10  2† 12  5† 8  2† 8  1† 8  3†
MED+V 15  4 8  1†* 9  2† 7  2†* 7  2† 6  2† 7  3†
PaO2 (mmHg) MED 99.6  3.6 93.5  6.0† – 95.2  4.3† 98.7  3.6 101.8  6.8 105.5  5.2†
MED+V 98.8  8.5 91.8  3.3† – 98.0  4.3 99.1  3.6 104.3  3.4† 100.1  3.6*
PvO2 (mmHg) MED 36.3  6.3 26.2  2.1† – 28.3  2.0† 29.2  1.8† 31.1  3† 30.0  3.1†
MED+V 33.8  3.6 32.6  1.9†* – 31.8  3.1†* 31.1  3.1† 31.0  2.8† 35.9  4.1*
DO2 index (mL/min/kg) MED 14.9  5.2 7.9  1.1† – 8.9  1.3† 9.9  2.2† 13.5  6.4 19.7  8.1†
MED+V 13.7  3.1 10.8  1.4 – 10.3  2.9† 9.6  1.7† 10.0  2.4† 16.1  4.7
VO2 index (mL/min/kg) MED 3.3  1.0 3.3  0.3 – 3.2  0.4 3.5  1.0 4.0  1.1 6.9  3.7†
MED+V 3.8  1.2 3.0  0.4 – 3.1  0.7 3.0  0.5 3.3  0.8 3.7  1.1*
O2ER % MED 23.9  8.3 41.4  5.2† – 35.9  5.3† 34.6  3.9† 30.7  5.2† 34.5  6.4†
MED+V 27.9  6.9 28.2  3.7* – 30.4  6.2†* 31.9  6.0† 32.8  6.1† 23.9  7.4*
Plasma glucose concentration (mmol/L) MED 5.5  0.6 5.4  1.5 – 7.8  1.5† 9.4  2.6† 9.6  2.4† 8.9  2.1†
MED+V 5.7  0.5 5.7  0.5 – 6.5  1.2 6.9  1.5* 7.1  1.6* 7.0  1.3
PaO2, arterial oxygen tension; PvO2, central venous oxygen tension; DO2 index, oxygen delivery index; VO2 index, oxygen consumption index; O2ER%,
oxygen extraction ratio. Significant differences (P≤0.05) are labelled as (†) within treatment with respect to baseline at given time point and (*) between
the treatments in change from baseline at given time point.
TABLE 3: Pharmacokinetic parameters (meanSD) for
dexmedetomidine, levomedetomidine and vatinoxan of the same 6
horses as in Table 1
Drug Treatment
AUC0–120 min
(min ng/mL)
AUC60–
120 min
(min ng/mL) t½ (min)
Dexmedetomidine MED 72.0  18.0 17.3  5.9 19  5a
MED+V 58.3  17.2* 15.3  6* 20  4a
Levomedetomidine MED 29.3  11.7 9.4  3.5 20  3a
MED+V 24.7  11.7* 8.4  3.5 23  2a
Vatinoxan MED+V 8950  2851 – 75  28
AUC, area under time-concentration curve; t½, half-life of the drug.
aThese t½ estimates are uncertain because the calculations were based
on only three data points for each animal.
*Significant difference between MED and MED+V (P≤0.05).
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sedation. As expected, medetomidine, when administered alone, induced
immediate vasoconstriction (observed as increased MAP and SVRI), even if
MAP remained within clinically acceptable limits. From 60 min onwards
MAP and SVRI decreased with MED, likely due to prevailing central
sympatholytic effect of medetomidine [4]. In the presence of vatinoxan,
MAP decreased but remained within the reference range of standing
horses (94–140 mmHg) [20]. Furthermore, the calculated SVRI (describing
peripheral vasoconstriction) remained stable with MED+V throughout the
study period. The observations likely reflect the medetomidine-induced
vasoconstriction that vatinoxan alleviated, probably via its direct
antagonism of vascular a2-adrenoceptors. No bradycardia was observed
with MED+V, likely due to lack of baroreceptor responses in the context of
normal systemic vascular resistance [5]. The observed fall in heart rate with
MED+V can likely be attributed to reduced sympathetic tone. These
findings are consistent with previous studies on horses, in which vatinoxan
was administered simultaneously with single bolus doses of medetomidine
[9], detomidine [10] or romifidine [11]. Noticeably, the baseline MAP
readings in this study were unexpectedly high, which may reflect a stress
response of these unsedated horses, standing in stocks prior to the start of
the experiment. Similarly, stress and consequent moving of horses could at
least partially explain the relatively large variation in the CI measurements
at 120 min. The arterial catheters functioned normally and LiDCO system
displayed no errors during CI measurement. Certain drugs, including a2-
agonists, are known to interact with lithium sensors in vitro [21]. The
concentrations of dexmedetomidine in this study, however, were markedly
lower than those that caused interference with the sensor in vitro [21],
thus dexmedetomidine as a source of bias in cardiac output measurement
is therefore unlikely. Nevertheless, comparisons of the post-drug blood
pressure values to baseline and interpretation of CI measurements at
120 min should be treated with caution.
Decreased Qt is a recognised effect of medetomidine in horses [4,6,22].
In dogs, dexmedetomidine did not have a direct myocardial depressant
effect; the decrease in cardiac output and stroke volume were likely
consequences of its other haemodynamic effects [23]. Thus, it is plausible
that as SVR remained stable and bradycardia did not ensue with MED+V,
CI also remained unchanged. The increased CVP initially seen after
medetomidine and its attenuation by vatinoxan are in line with the other
haemodynamic findings of this study. Increased CVP suggests increased
preload, which has been attributed to peripheral and pulmonary
vasoconstriction caused by a2-agonists [6]. Interestingly, some evidence
also suggests that equine saphenous veins may express adrenergic
receptors [24], in which case medetomidine and vatinoxan may additionally
have direct effects on venous walls. Our CVP observations agree with a
previous study that combined vatinoxan with an i.v. bolus dose of
detomidine in horses [10]. In contrast, increased CVP has not been
consistently observed after medetomidine [4]. This could be partially
explained by the use of a smaller dose of medetomidine than in our study,
as the cardiovascular effects of medetomidine seem to be dose-dependent
within a certain range [6]. Finally, the cardiovascular suppression in horses
during CRI of medetomidine has been reported to be minor after the
changes following the medetomidine loading dose have waned [2].
Although there was also a tendency in this study for most of these
haemodynamic changes to occur early after the medetomidine loading
dose, these changes could be alleviated by vatinoxan.
In this study, vatinoxan had no detectable effect on the observed
transient (although minor) decrease in PaO2 after medetomidine.
Nevertheless, small but significant decreases in PvO2 after medetomidine
were observed, and were found to be alleviated by vatinoxan, similarly to
previous reports [4,22]. Furthermore, vatinoxan improved the O2ER, which
describes the amount of oxygen removed from blood by tissues. The
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oxygen extraction ratio increases in situations such as tissue hypoxia and
increased metabolic oxygen demand [25]. Thus, improved O2ER probably
reflects better tissue perfusion in horses receiving vatinoxan. The improved
PvO2 and O2ER with vatinoxan paralleled the improved haemodynamic
parameters (i.e. SVRI and CI) during the CRI, as presumed. The improved
oxygenation and tissue perfusion may become clinically important in
sedation protocols for surgical procedures or in horses that have a
systemic illness and compromised cardiovascular function, such as horses
with severe colic.
a2-agonists are known to increase plasma glucose concentrations by
decreasing insulin secretion via activation of a2-adrenoceptors located on
pancreatic b-cells, and this was observed in this study as well with
medetomidine, as also previously reported [26]. Also, this effect was
alleviated by vatinoxan, probably via blockade of pancreatic a2-
adrenoceptors, as seen in dogs [27].
In this study, medetomidine decreased borborygmi (as assessed by
auscultation) as has been reported previously [26]. a2-adrenoceptors with
an inhibitory effect on motility are expressed in equine jejunum [28]. In
addition, the equine caecum and colon are postulated to be more sensitive
to the effects of medetomidine than the jejunum [29], which is supported
by a previous observation of decreased faecal output after medetomidine
for 3.5–5 h [26]. This increases the risk for post-sedation colon impaction
and colic. In our study, vatinoxan alleviated the decrease in gastrointestinal
borborygmi scores throughout the observation period, and the scores
were restored to baseline levels sooner in the presence of vatinoxan. This
is consistent with previous studies where vatinoxan prevented [10] and
reversed [12] gastrointestinal hypomotility after administration of
detomidine. Direct antagonism of vatinoxan at the level of intestinal a2-
adrenoceptors could explain the improved gastrointestinal motility. Thus,
vatinoxan may reduce the risk of post-sedation colic in horses, especially
after more prolonged sedation with a CRI of medetomidine.
All horses were sedated after administration of medetomidine.
Vatinoxan slightly yet significantly decreased the mean sedation scores
during the first 20 min. The decreased sedation scores may at least in
part be explained by the differences in the plasma concentrations of
dexmedetomidine between the two treatments. Vatinoxan has previously
been reported to enhance the distribution and clearance of i.v. bolus
doses of detomidine [10] and romifidine [11] in horses, most likely
through changes in haemodynamics. In the aforementioned studies,
vatinoxan decreased the mean sedation scores [11] or areas under the
time-sedation score curves, albeit the maximum sedation scores were
unaffected [10]. Furthermore, in dogs the distribution of an i.v. bolus
dose of dexmedetomidine was increased by concomitant vatinoxan
mainly during the first 10 min, after which the elimination curves of
dexmedetomidine with and without vatinoxan appeared parallel [30].
Although pharmacokinetics were not investigated in such detail in this
study, the sedation scores differed between the treatments only in the
first 20 min following the administration of vatinoxan and the loading
dose of medetomidine. This supports the concept of vatinoxan
promoting the early distribution of dexmedetomidine. In horses, the half-
lives of medetomidine and dexmedetomidine are short (11–29 min [2,26]
and 19–29 min [3,22] respectively). Whilst, the pharmacokinetic steady
state of medetomidine is attained within approximately 30 min using a
CRI and a smaller loading dose (5 lg/kg) than that used in this study [2].
In comparison, the half-life of vatinoxan in horses has been reported to
be markedly longer than that of (dex)medetomidine; over 2 h when
given alone [11]. In this study, vatinoxan half-life was approximately
75 min (mean) in the presence of medetomidine. Thus, it is plausible
that using a medetomidine CRI, steady state was achieved in our horses,
and, furthermore, that the antagonistic effect of the single dose of
vatinoxan persisted during this phase without major impact on the
sedation level.
A limitation of this study was the use of healthy, unstimulated animals.
The effects of vatinoxan on sedation quality and on the potential analgesic
effect of medetomidine when a nociceptive stimulus is applied, remains to
be investigated.
In conclusion, vatinoxan administered simultaneously with a loading
dose of medetomidine improved cardiovascular and gastrointestinal
function during a CRI of medetomidine in healthy horses. This was
achieved without noticeable side effects or clinically relevant effects on
sedation scores. By improving the haemodynamics of horses during
sedation with medetomidine, vatinoxan could also improve tissue
perfusion during sedation. Improved gastrointestinal motility may reduce
the risk of post-sedation colic. The safety of vatinoxan in clinically ill horses
and its effects on the analgesic efficacy of a2-agonists warrant further
studies.
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